FTC Fights Nixing Of AndroGel Reverse Payment Suit
The Federal Trade Commission is challenging the dismissal of its claims accusing Solvay Pharmaceuticals Inc. of paying generic-drug makers not to compete with its testosterone supplement AndroGel, continuing the fight over...To view the full article, register now.
Already a subscriber? Click here to view full article